AR127445A1 - CLAUDIN 18.2 BINDING ANTIBODIES AND FRAGMENTS THEREOF - Google Patents
CLAUDIN 18.2 BINDING ANTIBODIES AND FRAGMENTS THEREOFInfo
- Publication number
- AR127445A1 AR127445A1 ARP220102889A ARP220102889A AR127445A1 AR 127445 A1 AR127445 A1 AR 127445A1 AR P220102889 A ARP220102889 A AR P220102889A AR P220102889 A ARP220102889 A AR P220102889A AR 127445 A1 AR127445 A1 AR 127445A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- claudin
- nucleic acid
- isolated nucleic
- fragments
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 3
- 102000002029 Claudin Human genes 0.000 title abstract 2
- 108050009302 Claudin Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
En el presente documento, se divulgan anticuerpos y fragmentos de anticuerpos capaces de unirse a claudina 18.2. Reivindicación 25: Un ácido nucleico aislado que codifica el anticuerpo o el fragmento de unión a antígeno de este de una cualquiera de las reivindicaciones precedentes. Reivindicación 26: Un vector de expresión caracterizado porque comprende el ácido nucleico aislado de la reivindicación 25. Reivindicación 27: Una célula hospedadora caracterizada porque comprende la molécula de ácido nucleico aislada de la reivindicación 25 o el vector de expresión de la reivindicación 26. Reivindicación 28: Una composición farmacéutica caracterizada porque comprende el anticuerpo o el fragmento de unión a antígeno de este de una cualquiera de las reivindicaciones 1 a 22 o un conjugado del anticuerpo de la reivindicación 23 o 24 y un excipiente farmacéuticamente aceptable.Disclosed herein are antibodies and antibody fragments capable of binding to claudin 18.2. Claim 25: An isolated nucleic acid encoding the antibody or the antigen-binding fragment thereof of any one of the preceding claims. Claim 26: An expression vector characterized in that it comprises the isolated nucleic acid of claim 25. Claim 27: A host cell characterized in that it comprises the isolated nucleic acid molecule of claim 25 or the expression vector of claim 26. Claim 28 : A pharmaceutical composition characterized in that it comprises the antibody or the antigen-binding fragment thereof of any one of claims 1 to 22 or a conjugate of the antibody of claim 23 or 24 and a pharmaceutically acceptable excipient.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163271633P | 2021-10-25 | 2021-10-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127445A1 true AR127445A1 (en) | 2024-01-24 |
Family
ID=86160408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102889A AR127445A1 (en) | 2021-10-25 | 2022-10-25 | CLAUDIN 18.2 BINDING ANTIBODIES AND FRAGMENTS THEREOF |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4423136A1 (en) |
| AR (1) | AR127445A1 (en) |
| WO (1) | WO2023070201A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020009514A (en) * | 2018-03-14 | 2020-12-07 | Beijing Xuanyi Pharmasciences Co Ltd | Anti-claudin 18.2 antibodies. |
| CN109762067B (en) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | Antibodies that bind human Claudin18.2 and uses thereof |
| KR102649942B1 (en) * | 2019-11-05 | 2024-03-25 | 라노바 메디신즈 리미티드 컴파니 | Antibody-drug conjugates targeting claudin 18.2 |
-
2022
- 2022-10-25 EP EP22884824.8A patent/EP4423136A1/en active Pending
- 2022-10-25 AR ARP220102889A patent/AR127445A1/en unknown
- 2022-10-25 WO PCT/CA2022/051572 patent/WO2023070201A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023070201A1 (en) | 2023-05-04 |
| EP4423136A1 (en) | 2024-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125429T1 (en) | INTERLEUKIN-21 MUTEINS AND METHODS OF THERAPEUTIC TREATMENT | |
| CY1121132T1 (en) | FULLY-HUMAN MONOCLONE ANTIBODIES ANTI-vap-1 | |
| CY1113089T1 (en) | Human Monoclonal Antibodies to Specific Protective Membrane Antigen (PSMA) | |
| AR111207A1 (en) | ANTI-LAG3 ANTIBODIES | |
| CY1122270T1 (en) | ANTI-FACTOR XI MONOCLONAL ANTIBODIES AND METHODS OF USING THEREOF | |
| CO2019006565A2 (en) | Novel amanitin conjugate | |
| AR111203A1 (en) | IMMUNOCATE PLAYERS | |
| AR110101A1 (en) | MEMBERS OF UNION (2) | |
| AR072897A1 (en) | COMPOSITIONS AND METHODS FOR ANTIBODIES GOING TO COMPLEMENT PROTEIN C5 | |
| BR112016002614A2 (en) | immunocytokine, nucleic acid, vector, host cell and pharmaceutical composition | |
| BR112016013347A8 (en) | anti-il-33 neutralizing human monoclonal antibody, pharmaceutical composition, cytokine expression inhibitor, epitope, nucleic acid molecule, vector, host cell, method of production and use thereof. | |
| AR095432A1 (en) | PROTEINS OF UNION TO ANTIGEN | |
| WO2021227307A8 (en) | Anti-cd73 antibody and use thereof | |
| BR112012005713A2 (en) | langerhans cell targeted vaccines. | |
| CY1123760T1 (en) | RECOMBINANT AAV VECTORS EXPRESSING OSTEOPROTECTIVE GENES, INCLUDING HAS2 AND LUBRICIN, USEFUL IN THE THERAPEUTIC TREATMENT OF OSTEOARTHRITIS AND RELATED JOINT DISEASES IN MAMMALS | |
| NO20091283L (en) | Human antibodies that bind CXCR4 and its applications | |
| NO20081987L (en) | Human monoclonal antibodies to CD70 | |
| BR112019005129A2 (en) | anti-pd-1 antibodies | |
| CL2021002168A1 (en) | Tumor associated peptide; nucleic acid; expression vector; recombinant host cell; method for producing the peptide; activated t lymphocytes and their production method; antibody; tcr; use to treat cancer; kit and pharmaceutical composition; method for producing vaccine; and Aptary (divisional application no. 201702407). | |
| AR109683A1 (en) | ANTIBODIES AGAINST FACTOR XI AND ITS USES | |
| AR110755A1 (en) | BONE DIRECTED ANTIBODIES | |
| AR105978A1 (en) | THERMAL STROMAL LYMPHOPYETIN BINDING MOLECULES (TSLP) AND METHODS OF USE OF THE MOLECULES | |
| CO2019003759A2 (en) | Antibodies that bind to the zika virus envelope protein and uses thereof | |
| CL2021002792A1 (en) | Monoclonal antibody that specifically binds to gitr | |
| EA201991845A1 (en) | PHARMACEUTICAL COMBINATIONS CONTAINING AN ANTIBODY TO LY75 |